ITGAV and prostate carcinoma: Increased expression of ITGAV has been reported as a prognostic marker in diverse cancer types (breast cancer, prostate cancer, ovarian cancer, glioblastoma, myeloma, hepatocellular carcinoma, skin carcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, pancreatic adenocarcinoma and so on)9,10,48,55–62.